Table 3 Univariate analysis of predictors for recipient overall survival
HR (95% CI) | P value | |
|---|---|---|
Donor variables | ||
Age (reference Group I) | < 0.001 | |
Group II | 1.097 (1.000–1.203) | 0.050 |
Group III | 1.153 (1.053–1.262) | 0.002 |
Group IV | 1.319 (1.164–1.493) | < 0.001 |
Race (reference White) | 0.778 | |
Black or African American | 1.008 (0.917–1.108) | 0.868 |
Asian | 0.983 (0.783–1.235) | 0.885 |
Hispanic/Latino | 1.011 (0.910–1.124) | 0.832 |
Other | 0.750 (0.483–1.165) | 0.200 |
ABO (reference A) | 0.123 | |
B | 0.925 (0.824–1.039) | 0.189 |
O | 1.053 (0.974–1.139) | 0.196 |
AB | 0.961 (0.782–1.181) | 0.706 |
Gender | 1.005 (0.969–1.042) | 0.781 |
Cause of death (reference Anoxia) | 0.002 | |
Cerebrovascular/stroke | 1.112 (1.019–1.214) | 0.017 |
Head trauma | 0.960 (0.874–1.055) | 0.397 |
CNS tumor | 0.452 (0.215–0.950) | 0.036 |
Other | 0.955 (0.722–1.263) | 0.747 |
DCD | 1.052 (0.916–1.208) | 0.476 |
Height (cm) | 0.997 (0.994–1.000) | 0.085 |
Weight (kg) | 1.000 (0.999–1.002) | 0.587 |
Recipient variables | ||
Age | 1.018 (1.013–1.024) | < 0.001 |
Gender (F vs. M) | 0.972 (0.931–1.015) | 0.195 |
Race (reference White) | < 0.001 | |
Black or African American | 1.177 (1.050–1.320) | 0.005 |
Asian | 0.756 (0.645–0.885) | < 0.001 |
Hispanic/Latino | 0.852 (0.767–0.946) | 0.003 |
Other | 0.965 (0.706–1.320) | 0.826 |
ABO (reference A) | 0.226 | |
B | 0.946 (0.844–1.061) | 0.345 |
O | 1.044 (0.965–1.130) | 0.28 |
AB | 0.927 (0.773–1.111) | 0.41 |
Underlying liver disease (reference HCV) | < 0.001 | |
HBV | 0.687 (0.586–0.804) | < 0.001 |
Alcohol | 0.905 (0.796–1.029) | 0.126 |
NASH | 1.014 (0.890–1.154) | 0.839 |
Other | 1.038 (0.922–1.169) | 0.535 |
Height (cm) | 1.003 (1.000–1.007) | 0.071 |
Weight (kg) | 1.000 (0.998–1.002) | 0.849 |
Warm ischemia time (min) | 1.000 (0.998–1.003) | 0.674 |
Cold ischemia time (h) | 0.999 (0.986–1.013) | 0.915 |
BMI | 0.997 (0.990–1.003) | 0.303 |
MELD | 1.016 (1.012–1.020) | < 0.001 |
Albumin (g/dl) | 0.893 (0.848–0.940) | < 0.001 |
Bilirubin (mg/dl) | 1.013 (1.008–1.017) | < 0.001 |
INR | 1.084 (1.040–1.131) | < 0.001 |
Creatinine (mg/dl) | 1.086 (1.061–1.111) | < 0.001 |
Sodium (mmol/L) | 0.991 (0.983–0.999) | 0.034 |
Tumor staging (beyond vs. within Milan) | 1.420 (1.160–1.738) | 0.001 |
Tumor nubmer | 1.113 (1.043–1.187) | 0.001 |
Largest tumor diameter (cm) | 1.065 (1.045–1.086) | < 0.001 |
Sum of tumor diameters (cm) | 1.061 (1.043–1.079) | < 0.001 |
AFP value (ng/ml) > 400 | 1.928 (1.599–2.325) | < 0.001 |
Pretransplant treatment | 0.998 (0.912–1.091) | 0.958 |
Immunosuppression Induction (reference anti-CD25) | 0.514 | |
Thymoglobulin | 1.074 (0.921–1.253) | 0.362 |
Anti-CD25 + Thymoglobulin | 1.370 (0.612–3.064) | 0.444 |
Maintenance at discharge | ||
Tacrolimus | 0.884 (0.819–0.954) | 0.002 |
Cyclosporine | 1.127 (0.912–1.391) | 0.269 |
Sirolimus | 1.157 (0.969–1.382) | 0.108 |
Mycophenolate mofetil | 0.915 (0.852–0.982) | 0.014 |
Steroids | 0.898 (0.832–0.968) | 0.005 |